Our Thinking

How big is the market for…?

We often are asked the size of the market for various segments of the bio/pharma contract services industry. In response, we’ve developed a resource page that addresses these questions. To learn about the size of these market segments and others…

Trend Reports

CMO Scorecard: Outsourcing of NDA Approvals and CMO Performance

Our research team crunched the numbers on 2014 drug approvals authorized by FDA’s CDER, CBER, Fast Track and Breakthrough drugs, and selected EMA approved drugs. The bottom line of this report is that…


CDMOs Cautiously Address Expansion

These are high times for contract development and manufacturing organizations (CDMOs) and contract research organizations (CROs). A record flood of external financing is flowing into the bio/pharmaceutical industry. Global bio/pharmaceutical companies are …

Lead Sheet

Real-time Expert BD Intelligence

CROs, CMOs and CDMOs worldwide depend on the PharmSource Lead Sheet for fresh leads, up-to-date contact information and reliable market intelligence. Quickly scout well-targeted new business opportunities. Learn more

Strategic Advantage

Proprietary Global Sourcing Intelligence in an Instant

Decision-makers at CMOs, CDMOs and Bio/Pharma companies rely on Strategic Advantage, to understand industry trends and company capabilities. Quickly get hard-to-find information and benefit from PharmSource’s trademark quantitative approach to analysis. Learn more

Market Intelligence

CFDA Approvals See First Increase Since 2011

Reversing the trend seen over the last few years, approvals for new drug products and clinical trials in China rose in 2014.

The increase could represent less a true increase and more a normalization of review and approval rates, suggested Carl Williams, a former US FDA investigator with experience in China. The CFDA’s increased attention to GMP compliance likely was…